Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmethylsertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethylsertraline SCHEMBL29737233 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29481074 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4781834 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL29690290 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL263132 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL9611184 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL263142 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL260449 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL259292 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29757858 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0386997-A2 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER INC. (US) | 1990-09-12 | — | — | EP | claimed |
| EP-2816024-B1 | Chiral amines | SUNOVION PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2816024-A1 | Chiral amines | Sunovion Pharmaceuticals Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. | 2014-10-23 | — | — | US | disclosed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329950-B2 | Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329950-B2 | Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2455075-A1 | Combinations of Eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, & Cognitive Disorders | Sepracor Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120123164-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120123164-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2007143267-A2 | TREATMENT OF PAIN DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | SEPRACOR INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007006003-A2 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS | SEPRACOR INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-0386997-A2 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER INC. (US) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A2 130/4885SLC6A4 38/4885SLC6A3 114/4885 |
| US-20070282007-A1 | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE | HTR4, HTR1D, HTR1A | SLC6A2 52/4885SLC6A4 21/4885SLC6A3 60/4885 |
| US-20120123164-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A2 130/4885SLC6A4 38/4885SLC6A3 114/4885 |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A2 130/4885SLC6A4 38/4885SLC6A3 114/4885 |
| US-20080293726-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A2 130/4885SLC6A4 38/4885SLC6A3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.